



MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

ABN 14 106 340 667

FACTORY 7, 56 SMITH ROAD, SPRINGVALE, VICTORIA 3171, AUSTRALIA

Telephone: +61 3 9547 1888 Facsimile: +61 3 9547 0262

Web: www.medicaldev.com Email: mdi@medicaldev.com

ASX RELEASE

MVP'S REGISTRATION PROGRAMME BEARS EARLY FRUIT

Medical Developments International Limited (ASX Code: MVP) announces a number of positive developments in its quest to take its pain relief drug to a world market.

Drug Registration Update

Overall MVP's registration programme is progressing well:

- **Pakistan.** MVP has been notified that the drug was registered and approved for marketing this week. MVP expects to announce its first sale into Pakistan shortly.
- **GCC countries (Saudi Arabia, Bahrain, Qatar, Oman, UAE and Kuwait).** This application is due to be reviewed by the relevant authorities this month. Assuming it is in order, an inspection of MVP's manufacturing facilities will be undertaken for approval. Registration by September 2005 is on track.
- **Iran.** MVP's manufacturing facilities have now been approved. The product registration application will be filed this month. Registration is expected by March 2005, ahead of schedule.
- **USA.** MVP met with the FDA on 3 December. The FDA have confirmed that a New Drug Application (NDA) called a 505(b)(2) is the appropriate registration pathway. Some additional **pre-clinical** evidence is required to augment the data already held by MVP. MVP is seeking to complete these pre-clinical trials in the first half of 2005. The FDA has indicated that a **clinical** trial completed earlier this year in a major Australian Hospital together with the extensive body of literature held by MVP will likely meet its requirements for clinical data. MVP expects to file the NDA in the second half of 2005.
- **India.** This application is complete and will be filed shortly.
- **Singapore.** MVP met with the Singapore Regulatory Authority (HSA) in late October. The application for registration will be filed in December and registration is expected in mid 2005, ahead of schedule.
- **Canada.** MVP is in discussions with Health Canada to agree the registration pathway. It is expected that these discussions will be finalised by March 2005.
- **South Africa.** This application is being finalised and will likely be ready to file in January/February 2005.

Sales and Trials Update

MVP's sales efforts are also progressing well. Field trials of Pentrox™ are underway in the Armed Forces of **India, UAE, Nepal and Japan.** **New Zealand** Defence Force has approved the use of Pentrox™. The **UK** Armed Forces also plan to evaluate Pentrox™ for use in the field.

Elsewhere, Pentrox™ is being trialled in **Iran** (hospitals & pre-hospital emergency pain relief), **New Guinea** (ambulance) and a trial in **Afghanistan** is expected to commence shortly.

MVP believes that the drug has much wider applications than ambulance and military use. Potential applications include use in minor surgical procedures, dressing changes after surgery or burns, in emergency departments, transport of patients with severe pain between hospital departments, radiology procedures, oncology and painful post-operative physiotherapy. The company notes that there are a number of major Hospitals in Australia currently trialling or about to trial the drug for some of these applications.

MVP is confident that it will generate sales in Iran, UAE, New Zealand and Pakistan before the end of June 2005. In addition, MVP believes there are sales opportunities (with a lower probability) in FY2005 in Qatar, Oman, Saudi Arabia, Nepal, Brunei and India.

Company Profile

MVP is a leader in emergency pain relief and respiratory products. The Company manufactures a pre-hospital and emergency pain relief product called Pentrox™, an analgesic and inhaler device. Commonly referred to as the "Green Whistle", Pentrox™ has been widely used in Australian Ambulance Services, the Australian Defence Forces, and in extreme sports for over 20 years. The analgesic is the only volatile anaesthetic agent that causes profound analgesia at concentrations that do not cause drowsiness or unconsciousness.

Further Information: Mr Chris Weaver
Chief Executive Officer
03 9547 1888

Mr David Williams
Chairman
0414 383 593